Escitalopram in the Treatment of Postpartum Depression

Summary

This will be an 8-week, open-label trial evaluating the efficacy of escitalopram as monotherapy in the treatment of patients with postpartum depression (PPD). The acute phase of the study will consist of an 8 week treatment phase. Treatment of eligible participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presence of depressive symptoms and side effects up to a maximum of 20mg/day. Study objectives are: 1. to investigate the efficacy of escitalopram in the treatment of PPD. 2. to assess the effects of escitalopram on patients quality of life.

Timeline

Start

2008-04

Primary completion

2009-05

Completion

2009-05

Drugs

Indications